logo
Share SHARE
FONT-SIZE Plus   Neg

Nestlé FY12 Profit Rises - Quick Facts

Nestlé Group (NSTR.L, NSRGY.PK) reported fiscal 2012 net profit of 10.6 billion Swiss francs; an increase of 1.1 billion francs from last year. Profit per share increased 12.2% to 3.33 francs. Underlying earnings per share in constant currencies were up 7.5%. Reported sales were up 10.2% to 92.2 billion francs. Organic growth was 5.9%, and was composed of 3.1% real internal growth and 2.8% pricing.

Nestlé Board will propose an increase in the dividend to 2.05 francs per share at the Annual General Meeting. The net dividend will be payable as from 18 April 2013. The last trading day with entitlement to receive the dividend is 12 April 2013.

Looking forward, Nestlé Group said the environment looks to be every bit as challenging in 2013 as it was in 2012. The Group expects to deliver the Nestlé Model once again in 2013: organic growth between 5% and 6% together with an improved trading operating profit margin and underlying earnings per share in constant currency, as well as improvement in capital efficiency.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Sony announced Project Field, a new play way to bring card games to life, along with a host of smartphone games at an event in Japan, aiming to accelerate mobile drive. Project Field is a Japan-only card collection platform where actual physical cards will work with a smartphone app. The first title to be announced is based on Yo-kai Watch for mobile. There is no news about an international releas Shares of Credit Suisse Group AG gained around 8 percent in the morning trading in Zurich after the Swiss banking giant raised its group cost savings target, and also confirmed its medium-term 2018 pre-tax income target. It is almost the end of the year. With the exception of a few, many of the biotech stocks, like the following, on which investors had bet big this year have served up only heartbreak. Now, let's take a look at some of the pending clinical trial catalysts of this month, which will make it a December to remember.
comments powered by Disqus
Follow RTT